Related Experiment Videos
[Experiences with sultamicillin granules in pediatric patients]
The Japanese Journal of Antibiotics
|December 1, 1988
Summary
Sultamicillin (SBTPC), a combination of sulbactam and ampicillin, demonstrated high clinical efficacy (95.7%) in treating pediatric infections. This antibiotic combination proved safe and well-tolerated in young patients.
Area of Science:
- Pharmacology
- Microbiology
- Pediatric Medicine
Context:
- Beta-lactamase inhibitors are crucial for combating antibiotic resistance.
- Ampicillin's spectrum is often limited by bacterial resistance mechanisms.
- Sultamicillin combines ampicillin with sulbactam to overcome resistance.
Purpose:
- To evaluate the clinical efficacy and safety of sultamicillin (SBTPC) granules in pediatric patients.
- To assess the effectiveness of sulbactam (SBT) in restoring ampicillin's (ABPC) spectrum against resistant bacteria.
Summary:
- Sultamicillin (SBTPC) is an ester combination of sulbactam (SBT) and ampicillin (ABPC) at a 1:1 ratio.
- Sulbactam acts as a beta-lactamase inhibitor, enhancing ampicillin's activity against resistant bacterial strains.
- In a study of 26 pediatric patients, SBTPC granules were administered, with 23 patients evaluated for clinical efficacy.
- A high clinical efficacy rate of 95.7% was observed, indicating significant effectiveness in treating pediatric infections.
Impact:
- Sultamicillin (SBTPC) shows high effectiveness and safety for treating pediatric infectious diseases.
- The drug broadens the antimicrobial spectrum of ampicillin, addressing bacterial resistance.
- Results support SBTPC as a valuable therapeutic option in pediatric infectious disease management.